Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Trista K Hinz"'
Autor:
Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan, D Ross Camidge, Marileila Varella-Garcia, Robert C Doebele
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82236 (2013)
The targeting of oncogenic 'driver' kinases with small molecule inhibitors has proven to be a highly effective therapeutic strategy in selected non-small cell lung cancer (NSCLC) patients. However, acquired resistance to targeted therapies invariably
Externí odkaz:
https://doaj.org/article/ac60de8b4c2f4279b38e26b9cd47f632
Autor:
Kathryn E Ware, Marianne E Marshall, Lydia R Heasley, Lindsay Marek, Trista K Hinz, Paula Hercule, Barbara A Helfrich, Robert C Doebele, Lynn E Heasley
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e14117 (2010)
Despite initial and sometimes dramatic responses of specific NSCLC tumors to EGFR TKIs, nearly all will develop resistance and relapse. Gene expression analysis of NSCLC cell lines treated with the EGFR TKI, gefitinib, revealed increased levels of FG
Externí odkaz:
https://doaj.org/article/46fcf9c01b6b4995a8fad7b7b0c4e4d2
Autor:
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, Natalia J. Gurule, Andre Navarro, Anh T. Le, Amber M. Johnson, Jeff Kwak, Diana I. Polhac, Eric T. Clambey, Mary Weiser-Evans, Daniel T. Merrick, Michael C. Yang, Tejas Patil, Erin L. Schenk, Lynn E. Heasley, Raphael A. Nemenoff
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that control this response ar
Externí odkaz:
https://doaj.org/article/8192c462eff74d50be9a1f7314bb046e
Autor:
Laura Schubert, Anh T. Le, Trista K. Hinz, Andre C. Navarro, Sarah K. Nelson-Taylor, Raphael A. Nemenoff, Lynn E. Heasley, Robert C. Doebele
Publikováno v:
Biology Open, Vol 12, Iss 8 (2023)
Externí odkaz:
https://doaj.org/article/b9e7e4875d3e41e1b3b2c29b66661bcb
Autor:
Daniel J. Sisler, Trista K. Hinz, Anh T. Le, Emily K. Kleczko, Raphael A. Nemenoff, Lynn E. Heasley
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRASG12C protein have been developed and demonstrate clinical response rates of 37-43%. Importa
Externí odkaz:
https://doaj.org/article/cb227c2f9f5440f7a6ba0d3df80f32ec
Autor:
Natalia J. Gurule, Caroline E. McCoach, Trista K. Hinz, Daniel T. Merrick, Adriaan Van Bokhoven, Jihye Kim, Tejas Patil, Jacob Calhoun, Raphael A. Nemenoff, Aik Choon Tan, Robert C. Doebele, Lynn E. Heasley
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
Abstract Tyrosine kinase inhibitors (TKIs) targeting EGFR-mutant lung cancers promote a range of tumor regression responses to yield variable residual disease, a likely incubator for acquired resistance. Herein, rapid transcriptional responses induce
Externí odkaz:
https://doaj.org/article/d5ae4b79688c4b8094ee97ddf345427d
Autor:
Sean P. Korpela, Trista K. Hinz, Ayman Oweida, Jihye Kim, Jacob Calhoun, Robert Ferris, Raphael A. Nemenoff, Sana D. Karam, Eric T. Clambey, Lynn E. Heasley
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-15 (2021)
Abstract Background Epidermal growth factor receptor (EGFR) is frequently amplified or overexpressed in head and neck squamous cell carcinoma (HNSCC) and is a clinically validated target for the therapeutic antibody, cetuximab, in the management of t
Externí odkaz:
https://doaj.org/article/6d59c8e01ce041bf87fdfd079c2692c1
Autor:
Laura Schubert, Anh T. Le, Trista K. Hinz, Andre Navarro, Sarah K. Nelson-Taylor, Raphael A. Nemenoff, Lynn E. Heasley, Robert C. Doebele
CRISPR/Cas9 gene editing technology is an indispensable and powerful tool in the field of cancer biology. To conduct successful CRISPR-based experiments, it is crucial that sgRNAs generate their designed alterations. Here, we describe a simple and ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed911f63f0b6d8ac15c562472565b115
https://doi.org/10.1101/2023.04.06.535912
https://doi.org/10.1101/2023.04.06.535912
Autor:
Lynn E. Heasley, Sven Perner, Joseph M. Gozgit, Arne Warth, Hans Hoffmann, Raphael A. Nemenoff, Mary C. Weiser-Evans, Diana Boehm, Emily K. Kleczko, Kyle A. Olszewski, Anne von Mässenhausen, Trista K. Hinz, Lindsay A. Marek
Figure S1. Fluorescence in situ hybridization (FISH) analysis of FGFR1 gene copy number status in mesothelioma cell lines. Figure S2. Bioluminescence imaging of orthotopically implanted H226 tumors treated with or without ponatinib. Supplementary Tab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72aaca3af0c29d5b3500aecdfa0171b1
https://doi.org/10.1158/1541-7786.22514688.v1
https://doi.org/10.1158/1541-7786.22514688.v1
Autor:
Sven Perner, Lynn E. Heasley, Antonio Jimeno, Aik-Choon Tan, Jihye Kim, Andreas Schroeck, Friedrich Bootz, Tobias Van Bremen, Fred R. Hirsch, Justin R. Eagles, Emily K. Kleczko, Wenzel Vogel, Diana Boehm, Robert Kirsten, Carsten Golletz, Antonia Göke, Brigitte Lankat-Buttgereit, Anne von Maessenhausen, Maike Bode, Rakesh Sharma, Petros Yoon, Lindsay A. Marek, Trista K. Hinz, Alina Franzen, Friederike Göke
Purpose: FGFR1 copy-number gain (CNG) occurs in head and neck squamous cell cancers (HNSCC) and is used for patient selection in FGFR-specific inhibitor clinical trials. This study explores FGFR1 mRNA and protein levels in HNSCC cell lines, primary t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bda53d4019a9c42e488c2a7b8d21960
https://doi.org/10.1158/1078-0432.c.6524013
https://doi.org/10.1158/1078-0432.c.6524013